Cytochrome P450 3A expression and activity in the rabbit lacrimal gland: Glucocorticoid modulation and the impact on androgen metabolism

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 12, 2005, Pages 4697-4706

  Attar, Mayssa ^a,b   Ling, Kah Hiing John ^b   Tang Liu, Diane D S ^a,b   Neamati, Nouri ^a   Lee, Vincent H L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 BENZYLOXYQUINOLINE; ANDROGEN; ANDROGEN RECEPTOR; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A6; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; GLUCOCORTICOID; GLYCOPROTEIN P; HEMOPROTEIN; KETOCONAZOLE; MESSENGER RNA; PREGNANE X RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RETINOIC ACID; TESTOSTERONE; UNCLASSIFIED DRUG; 7-BENZYLOXYQUINOLINE; CELL RECEPTOR; CYTOCHROME P 450 CYP3A6 (RABBIT); CYTOCHROME P-450 CYP3A6 (RABBIT); ENZYME INHIBITOR; QUINOLINE DERIVATIVE; STEROID RECEPTOR; UNSPECIFIC MONOOXYGENASE;

ANDROGEN METABOLISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG INHIBITION; ENZYME ACTIVITY; IC 50; LACRIMAL GLAND; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTOSTERONE METABOLISM; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; LACRIMAL APPARATUS; MALE; METABOLISM; MICROSOME; PHYSIOLOGY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXAMETHASONE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HYDROXYLATION; LACRIMAL APPARATUS; MALE; MICROSOMES; P-GLYCOPROTEIN; QUINOLINES; RABBITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TESTOSTERONE;

EID: 27144541206     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0139     Document Type: Article

References (49)

1. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol. 1996;24:48-57.
2. Wilkinson GR. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman AJG, Limbird LE, Goodman Gilman A, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001:3-30.
3. Nebert DW, Adesnik M, Coon MJ, et al. The P450 gene superfamily: recommended nomenclature. DNA. 1987;6:1-11.
4. Wrighton SA, Thummel KE. CYP3A. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins; 2000:115-133.
5. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998;92:73-82.
6. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102:10l6-1023.
7. Blumberg B, Sabbagh W Jr, Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998;12:3195-3205.
8. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;300:1036-1045.
9. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004;277:3-9.
10. Leveille-Webster CR, Arias IM. The biology of the P-glycoproteins. J Membr Biol. 1995;143:89-102.
11. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995;13:129-134.
12. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225-1229.
13. Hagemeyer CE, Rosenbrock H, Ditter M, et al. Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain. Neuroscience. 2003;117:521-529.
14. Sarkar MA, Vadlamuri V, Ghosh S, et al. Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos. 2003;31:1-6.
15. Waxman DJ, Attisano C, Guengerich FP, et al. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys. 1988;263:424-436.
16. Borlak J, Schulte I, Thum T. Androgen metabolism in thymus of fetal and adult rats. Drug Metab Dispos. 2004;32:675-679.
17. Sullivan DA, Wickham LA, Rocha EM, et al. Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. Adv Exp Med Biol. 1998;438:11-42.
18. Moroi SE, Lichter PR. Ocular pharmacology. In: Hardman AJG, Limbird LE, Goodman Gilman A, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001:1821-1848.
19. Mircheff AK, Warren DW, Wood RL. Hormonal support of lacrimal function, primary lacrimal deficiency, autoimmunity, and peripheral tolerance in the lacrimal gland. Ocul Immunol Inflamm. 1996;4:145-172.
20. Azzarolo AM, Mircheff AK, Kaswan RL, et al. Androgen support of lacrimal gland function. Endocrine. 1997;6:39-45.
21. Sato EH, Sullivan DA. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome. Invest Ophthalmol Vis Sci. 1994;35:2632-2642.
22. Ono M, Rocha FJ, Sullivan DA. Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-1pr/1pr mouse model of Sjogren's syndrome. Exp Eye Res. 1995;61:659-666.
23. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-12o8.
24. Clark AF, Yorio T. Ophthalmic drug discovery. Nat Rev Drug Discov. 2003;2:448-459.
25. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584-589.
26. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114-2119.
27. Smith JA, Vitale S, Reed GF, et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol. 2004;122:151-156.
28. Southren AL, Altman K, Vittek J, et al. Steroid metabolism in ocular tissues of the rabbit. Invest Ophthalmol. 1976;15:222-228.
29. Starka L, Obenberger J. Testosterone metabolism in various tissues of the intact and inflamed rabbit eye. Ophthalmic Res. 1976;8:374-378.
30. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988;43:630-635.
31. Marill J, Cresteil T, Lanotte M, et al. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000;58:1341-1348.
32. Fowler SM, Riley RJ, Pritchard MP, et al. Amino acid 305 determines catalytic center accessibility in CYP3A4. Biochemistry. 2000;39:4406-4414.
33. Pearce RE, McIntyre CJ, Madan A, et al. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys. 1996;331:145-l69.
34. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 1964;239:2370-2378.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:E45.
36. Ortiz de Montellano PR. The cytochrome P450 oxidative system. In: Woolf TF, ed. Handbook of Drug Metabolism. New York: Marcel Dekker Inc.; 1999:109-130.
37. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994:270:414-423.
38. Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol. 2000;84:76-84.
39. Stresser DM, Turner SD, Blanchard AP. et al. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos. 2002;30:845-852.
40. Dalet C, Clair P, Daujat M, et al. Complete sequence of cytochrome P450 3c cDNA and presence of two mRNA species with 3′ untranslated regions of different lengths. DNA. 1988;7:39-46.
41. Potenza CL, Pendurthi UR, Strom DK, et al. Regulation of the rabbit cytochrome P-450 3c gene: age-dependent expression and transcriptional activation by rifampicin. J Biol Chem. 1989;264:16222-16228.
42. Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet. 2003;42:153-178.
43. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal mdr1 by rifampin. J Biol Chem. 2001;276:14581-14587.
44. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
45. Haag M, Fautrel A, Guillouzo A, et al. Expression of cytochromes P450 3A in mouse lung: effects of dexamethasone and pregnenolone 16alpha-carbonitrile. Arch Toxicol. 2003;77:145-149.
46. Rocha FJ, Wickham LA, Pena JD, et al. Influence of gender and the endocrine environment on the distribution of androgen receptors in the lacrimal gland. J Steroid Biochem Mol Biol. 1993;46:737-749.
47. Rosenblum C, Dengler RE Jr, Geoffroy RF. Ocular absorption of dexamethasone phosphate disodixim by the rabbit. Arch Ophthalmol. 1967;77:234-237.
48. Weijtens O, Schoemaker RC. Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109:1887-1891.
49. Sullivan DA, Belanger A. Cermak JM, et al. Are women with Sjogren's syndrome androgen-deficient? J Rheumatol. 2003;30:2413-2419.